Atlas Trials

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.

Clinical trial NCT00970229 · COMPLETED

Trial details

NCT number
NCT00970229
Sponsor
Institute for Neurodegenerative Disorders
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Parkinson DiseaseHuntington Disease
Start date
2009-07-01
Primary completion
2015-04-01
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.